

CLAIMS

What is claimed is:

1. A method of treating asthma in an individual comprising administering to the individual a therapeutically effective amount of an anti-TNF α antibody or an antigen binding fragment thereof.
2. The method of Claim 1 wherein the antibody is a chimeric antibody.
3. The method of Claim 2 wherein the chimeric antibody competitively inhibits binding of TNF α to the cA2 monoclonal antibody.
4. The method of Claim 2 wherein the chimeric antibody is the cA2 monoclonal antibody.
5. A method of treating airway inflammation in an individual comprising administering to the individual a therapeutically effective amount of an anti-TNF α antibody or an antigen-binding fragment thereof.
6. The method of Claim 5 wherein the antibody is a chimeric antibody.
7. The method of Claim 6 wherein the chimeric antibody competitively inhibits binding of TNF α to the cA2 monoclonal antibody.
8. The method of Claim 6 wherein the chimeric antibody is the cA2 monoclonal antibody.

9. A method of reducing accumulation in lungs of inflammatory cells associated with asthma in an individual in need thereof comprising administering to the individual a therapeutically effective amount of an anti-TNF α antibody or an antigen-binding fragment thereof.
- 5 10. The method of Claim 9 wherein the antibody is a chimeric antibody.
11. The method of Claim 10 wherein the chimeric antibody competitively inhibits binding of TNF α to the cA2 monoclonal antibody.
12. The method of Claim 10 wherein the chimeric antibody is the cA2 monoclonal antibody.

FOIA b 7 - DATED 09/04/2015